The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Crinetics Pharmaceuticals Inc shares valued at $137,500 were sold by Kalofonos Isabel on Jan 05 ’26. At $55.00 per share, Kalofonos Isabel sold 2,500 shares. The insider’s holdings dropped to 834 shares worth approximately $47062.62 following the completion of this transaction.
Also, ISABEL KALOFONOS purchased 2,500 shares, netting a total of over 116,825 in proceeds.
Before that, DANA PIZZUTI had added 5,000 shares to its account. In a trade valued at $232,750, the Officer bought Crinetics Pharmaceuticals Inc shares for $46.55 each.
As published in a research note from Goldman on January 12, 2026, Crinetics Pharmaceuticals Inc [CRNX] has been rated up from a Neutral to a Buy and the price target has been revised to $67. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in early July. As of March 25, 2025, Stifel has initiated its “Buy” rating for CRNX. Earlier on February 11, 2025, TD Cowen initiated its rating. Their recommendation was “a Buy” for CRNX stock.
Analyzing CRNX Stock Performance
On last trading session, Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] rose 1.82% to $56.43. The stock’s lowest price that day was $53.705, but it reached a high of $56.54 in the same session. During the last five days, there has been a surge of approximately 5.99%. Over the course of the year, Crinetics Pharmaceuticals Inc shares have jumped approximately 58.42%.
Support And Resistance Levels for Crinetics Pharmaceuticals Inc (CRNX)
RSI (Relative Strength Index) is 69.60 on the 14-day chart, showing neutral technical sentiment.
Is Crinetics Pharmaceuticals Inc subject to short interest?
Stocks of Crinetics Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.54 million shares to 13.33 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 13.87 million shares. A decline of -4.04% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 13.63 of the overall float, the days-to-cover ratio (short ratio) decline to 13.63.
Which companies own the most shares of Crinetics Pharmaceuticals Inc (CRNX)?
In terms of Crinetics Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 87 in the next 12 months, up nearly 56.98% from the previous closing price of $55.42. Analysts anticipate Crinetics Pharmaceuticals Inc stock to reach 143 by 2026, with the lowest price target being 67. In spite of this, 5 analysts ranked Crinetics Pharmaceuticals Inc stock as Buy at the end of 2026.
